Table 2:
Unweighted and weighted replication cohort patient characteristics stratified immunosuppressant exposure and LTL group
| Replication Cohort | Weighted Replication Cohort | ||||||
|---|---|---|---|---|---|---|---|
| IS Exposed (N=105) | IS Unexposed (N=220) | P-value | IS Exposed (N=112) | IS Unexposed (N=217) | P-value | SMD | |
| Cohort, n (%) | <0.01 | 0.24 | 0.28 | ||||
| UTSW | -- | -- | -- | -- | |||
| UCSF | 50 (48) | 120 (55) | 74 (66) | 117 (54) | |||
| Chicago | 14 (13) | 56 (26) | 14 (13) | 47 (22) | |||
| UCD | 41 (39) | 44 (20) | 24 (21) | 53 (24) | |||
| CUMC | -- | -- | -- | -- | |||
| ILD Diagnosis, n (%) | <0.01 | 0.70 | 0.13 | ||||
| fHP | 49 (47) | 77 (35) | 36 (32) | 84 (39) | |||
| CTD-ILD* | 18 (17) | 18 (8) | 14 (13) | 22 (10) | |||
| uILD | 38 (36) | 125 (57) | 62 (56) | 111 (51) | |||
| Age, mean (SD) | 63 (12) | 69 (10) | <0.01 | 68 (11) | 67 (11) | 0.58 | 0.11 |
| Male, n (%) | 49 (47) | 110 (50) | 0.66 | 54 (48) | 105 (49) | 0.98 | 0.01 |
| Ethnicity/Race, n (%) | 0.08 | 0.86 | 0.03 | ||||
| White | 59 (56) | 143 (65) | 73 (65) | 137 (63) | |||
| African American | 20 (19) | 41 (19) | 17 (15) | 37 (17) | |||
| Hispanic | 16 (15) | 19 (9) | 12 (11) | 24 (11) | |||
| Asian | 6 (6) | 14 (6) | 8 (7) | 16 (8) | |||
| Other† | 4 (4) | 3 (2) | 3 (3) | 3 (1) | |||
| Ever Smoker, n (%) | 46 (44) | 134 (61) | 0.01 | 73 (65) | 125 (57) | 0.51 | 0.11 |
| Family History ILD, n (%) | 13 (12) | 15 (7) | 0.14 | 11 (10) | 20 (9) | 0.84 | 0.04 |
| Lung Function, mean (SD) | |||||||
| FVC % predicted | 65 (16) | 71 (21) | <0.01 | 72 (16) | 70 (20) | 0.50 | 0.11 |
| DLCO % predicted | 50 (19) | 51 (21) | 0.62 | 50 (17) | 50 (21) | 0.85 | 0.03 |
| Radiographic UIP, n (%)† | |||||||
| UIP# | 8 (8) | 38 (17) | 0.03 | 10 (9) | 30 (14) | 0.41 | 0.12 |
| Honeycombing | 22 (21) | 56 (25) | 0.45 | 21 (19) | 45 (21) | 0.77 | 0.05 |
| IS Therapy, n (%) | |||||||
| Mycophenolate | 91 (87) | -- | -- | 99 (89) | -- | -- | -- |
| Azathioprine | 14 (13) | -- | -- | 13 (11) | -- | -- | -- |
| IS Exposure Years, median (IQR) | 1.5 (0.5, 2.0) | -- | -- | 1.7 (0.8, 2.0) | -- | -- | -- |
| Prednisone, n (%) | 87 (83) | 70 (32) | <0.01 | 50 (44) | 103 (48) | 0.72 | 0.07 |
| Leukocyte Telomere Length | |||||||
| LTL <10th percentile, n (%) | 21 (20) | 63 (29) | 0.13 | 26 (24) | 62 (29) | 0.61 | 0.12 |
| Age-adjusted LTL, median (IQR) | 0.2 (−0.3, 0.6) | 0.1 (−0.4, 0.5) | 0.12 | 0.1 (−0.3, 0.4) | 0.1 (−0.4, 0.5) | 0.75 | 0.03 |
| Follow-up Years, median (IQR) | 2.0 (2.0, 2.0) | 2.0 (1.1, 2.0) | 0.03 | 2.0 (2.0, 2.0) | 2.0 (1.4, 2.0) | 0.34 | 0.23 |
| Outcome, n (%) | |||||||
| Death within 2 years | 17 (16) | 42 (19) | 0.63 | 21 (19) | 39 (18) | 0.95 | 0.01 |
| Transplant within 2 years | 1 (1) | 3 (1) | 1.0 | 1 (1) | 2 (1) | 0.40 | 0.07 |
CTD-ILD diagnoses: scleroderma 19, rheumatoid arthritis 5, inflammatory myositis 6, mixed connective tissue disease 1, Sjogren’s syndrome 2, systemic lupus erythematosus 3
Other Ethnicity/Race: Middle Eastern 2, Native American 2, Pacific Islander 3
Radiograhic UIP incudes definite usual interstitial pneumonia
Abbreviations: LTL, leukocyte telomere length; IS, immunosuppression; SMD, standardized mean difference; UCSF, University of California San Francisco; ILD, interstitial lung disease; fHP, fibrotic hypersensitivity pneumonitis; CTD-ILD, connective tissue disease interstitial lung disease; uILD, unclassifiable interstitial lung disease; FVC, forced vital capacity, DLCO, diffusion capacity for carbon monoxide; UIP, usual interstitial pneumonia